up to now few years, the UK has witnessed a revolution in clinical body weight‑decline therapies — in the introduction of semaglutide (Wegovy®) to the growing reputation of tirzepatide (Mounjaro®). Now, A different name is drawing focus in the two clinical and general public health circles: Retat